AnaptysBio (ANAB)
NASDAQ:ANAB
Want to see ANAB full AI Analyst Report?
ANAB Stock Chart & Stats
$67.51
-$0.23(-1.55%)
At close: 4:00 PM EST
$67.51
-$0.23(-1.55%)
Day’s Range― - ―
52-Week Range$17.11 - $73.30
Previous CloseN/A
Volume154.73K
Average Volume (3M)588.14K
Market Cap
$1.67B
Enterprise Value$2.48B
Total Cash (Recent Filing)$286.45M
Total Debt (Recent Filing)$277.36M
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Aug 10, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding29,100,903
10 Day Avg. Volume534,548
30 Day Avg. Volume588,145
Financial Highlights & Ratios
PEG Ratio0.77
Price to Book (P/B)24.14
Price to Sales (P/S)3.83
P/FCF Ratio45.80
Enterprise Value/Market Cap1.48
Enterprise Value/Revenue10.66
Enterprise Value/Gross Profit9.16
Enterprise Value/Ebitda42.35
Forecast
1Y Price Target
$79.86Price Target Upside18.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.79
Revenue Forecast (FY)$121.64M
Bulls Say, Bears Say
Bulls Say
Royalty-focused Business ModelThe April 2026 spin-off refocused AnaptysBio as a royalty manager, keeping Jemperli and imsidolimab royalties and collaborations. A royalty-centric model lowers recurring R&D burn, stabilizes cash inflows tied to partner commercialization, and supports a lower-cost virtual operating structure over the medium term.
Improved Cash GenerationAnaptysBio produced strong operating and free cash flow in 2025 and maintained positive FCF in the trailing twelve months, with FCF roughly matching net income. This indicates credible cash conversion and improved operational discipline, enhancing the company's ability to fund obligations and support royalty payouts or corporate needs.
Strengthened Finance Leadership & GovernanceAdding a seasoned CFO via a performance-aligned consulting agreement and refreshing the board increases financial oversight during the strategic transition. Improved governance and experienced financial leadership enhance capital allocation, reporting cadence, and risk management over the medium term.
Bears Say
Deteriorated Balance Sheet LeverageEquity declined and leverage rose above 1x in the trailing twelve months, reducing the balance sheet cushion. Higher leverage limits financial flexibility, raises refinancing and covenant risk, and increases sensitivity to irregular royalty or milestone receipts over the next several quarters.
Lumpy, Partner-dependent RevenueRevenue spikes tied to milestone and licensing events produced volatility: a strong 2025 then a material TTM decline. Dependence on milestone timing and partner development outcomes makes top-line and cash flows unpredictable, complicating budgeting and increasing forecast risk for 2–6 months or longer.
Loss Of Internal R&D Pipeline After Spin-offThe spin-off moved substantial cash, IP and clinical programs to First Tracks, leaving AnaptysBio as a royalty-focused, virtual entity. This reduces direct control over drug development and the upside from creating new assets, making future growth more dependent on external collaborators and royalty performance.
AnaptysBio News
ANAB FAQ
What was AnaptysBio’s price range in the past 12 months?
AnaptysBio lowest stock price was $17.11 and its highest was $73.30 in the past 12 months.
What is AnaptysBio’s market cap?
AnaptysBio’s market cap is $1.67B.
When is AnaptysBio’s upcoming earnings report date?
AnaptysBio’s upcoming earnings report date is Aug 10, 2026 which is in 50 days.
How were AnaptysBio’s earnings last quarter?
AnaptysBio released its earnings results on May 12, 2026. The company reported -$1.84 earnings per share for the quarter, missing the consensus estimate of -$0.644 by -$1.196.
Is AnaptysBio overvalued?
According to Wall Street analysts AnaptysBio’s price is currently Undervalued.
Does AnaptysBio pay dividends?
AnaptysBio does not currently pay dividends.
What is AnaptysBio’s EPS estimate?
AnaptysBio’s EPS estimate is -0.13.
How many shares outstanding does AnaptysBio have?
AnaptysBio has 29,100,903 shares outstanding.
What happened to AnaptysBio’s price movement after its last earnings report?
AnaptysBio reported an EPS of -$1.84 in its last earnings report, missing expectations of -$0.644. Following the earnings report the stock price went down -4.414%.
Which hedge fund is a major shareholder of AnaptysBio?
Currently, no hedge funds are holding shares in ANAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AnaptysBio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$79.86 (18.29% Upside)
$79.86 (18.29% Upside)
Blogger Sentiment
Neutral
ANAB Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 135.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
268.86%
12-Months-Change
Fundamentals
Return on Equity
442.91%
Trailing 12-Months
Asset Growth
-21.89%
Trailing 12-Months
Company Description
AnaptysBio
AnaptysBio, Inc. is a biotechnology firm currently in the clinical development phase, dedicated to pioneering novel therapeutic agents aimed at treating inflammatory conditions and immuno-oncological diseases. The company's portfolio features several promising drug candidates. These include Imsidolimab, an antibody designed to block the interleukin-36 receptor (IL-36R), targeting diverse skin-related inflammatory disorders. Another key program is Rosnilimab, an anti-PD-1 agonist antibody, which works by enhancing PD-1 signaling to mitigate human inflammatory diseases driven by T-cells. Furthermore, ANB032, an anti-BTLA modulator antibody, addresses human inflammatory conditions linked to imbalances in lymphoid and myeloid immune cell function. Beyond these core assets, AnaptysBio is actively advancing numerous other antibody programs, moving them through preclinical and clinical development phases, often in partnership with other entities. Its strategic alliances include collaboration and licensing agreements with pharmaceutical giants GlaxoSmithKline, Inc. and Bristol-Myers Squibb. Additionally, the firm holds licensing agreements with United Kingdom Research and Innovation and Millipore Corporation. Established in 2005, the company originally operated under the name Anaptys Biosciences, Inc., before rebranding to AnaptysBio, Inc. in July 2006. Its headquarters are situated in San Diego, California.
ANAB Stock 12 Month Forecast
Average Price Target
$79.86
▲(18.29% Upside)
Technical Analysis
Meiragtx Holdings
―
Keros Therapeutics
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
―
Ownership Overview
2.32% Insiders
11.84% Mutual Funds
51.26% Other Institutional Investors
21.54% Public Companies and
Individual Investors